Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Iranian strikes on two of the Middle East's largest aluminium producers, Aluminium Bahrain and Emirates Global Aluminium, have amplified fears of severe global shortages. The conflict and closure of the Strait of Hormuz have already limited shipments to key export markets in the U.S. and Europe. Both producers reported damage and are assessing oper…
Vertical Aerospace Ltd. (NYSE:EVTL) announced a financing package of up to $800 million on March 30, 2026, comprised of senior secured convertible notes from Mudrick Capital Management and a convertible preferred facility plus an equity line from Yorkville Advisors. The financing mix aims to fund aircraft research and development, testing and manuf…
Chinese-born, U.S.-based sculptor Gao Zhen, known for satirical depictions of Mao Zedong, was tried in a closed hearing on charges of "defaming national heroes and martyrs." The one-day session in Sanhe City People’s Court concluded with no immediate verdict. Gao, detained in August 2024 during a family visit to China, faces up to three years in pr…
Remarks by Rheinmetall CEO Armin Papperger characterizing Ukrainian drone production as the work of 'housewives' using kitchen 3-D printers provoked strong reactions in Ukraine, including from President Volodymyr Zelenskiy, government officials and an online campaign under #MadeByHousewives. Rheinmetall later issued a statement expressing respect f…
Shares of cybersecurity companies fell on Monday after a leaked draft blog post from Anthropic described a new model, Claude Mythos (also called Capybara), as "far ahead of any other AI model in cyber capabilities." DA Davidson analysts say they do not expect frontier AI tools to displace incumbent security vendors, highlight continued CISO skeptic…
Eikon Therapeutics closed an upsized IPO in February 2026 raising $381 million, strengthening its balance sheet to advance multiple late-stage clinical programs primarily in oncology. Key trial enrollments completed in non-small cell lung cancer and progress continued for selective PARP1 inhibitors and a novel WRN helicase inhibitor. The company re…
Viridian Therapeutics reported that its Phase 3 REVEAL-1 trial of elegrobart in active thyroid eye disease met its primary endpoint with highly statistically significant results, including notable proptosis responder rates and diplopia resolution. Despite the clinical success, the company’s stock fell about 40% on the day. The study enrolled 132 pa…
U.S. equity markets plunged on Friday, pushing the major indices into correction territory amid renewed tensions in the Middle East and a spike in energy prices. Brent crude rose above $110 a barrel after incidents in the Strait of Hormuz heightened supply concerns, while benchmark Treasury yields climbed to their highest levels since last summer. …
Bank of America’s Industrial Momentum Indicator fell for a second month after a run-up that started in fall 2025 and extended into early 2026. Key inputs such as copper, fund manager positioning and the Truck Shipper Survey have flattened amid macro uncertainty. While the indicator’s longer-term path remains upward following a Q3 2025 trough, recen…
Connect Biopharma Holdings saw its stock climb following the release of multiple clinical study results for rademikibart, an anti-interleukin-4-receptor alpha antibody. Preliminary Phase 1 pharmacology data indicate rapid, sustained improvements in lung function after a single 300 mg intravenous dose, while a partner-run Phase 3 trial in China repo…
Jefferies analysts contend a recent rout in internet stocks - driven in part by concerns over AI disruption - has pushed valuations to unusually low levels and created buying opportunities. The firm upgraded Expedia Group and Instacart to Buy, citing underappreciated earnings power and growth drivers even as shares trade well below historical multi…
WISeKey's subsidiary WISeSat.Space successfully launched its 21st satellite equipped with SEALSQ's post-quantum QS7001 chip into Low Earth Orbit via SpaceX's Transporter-16 rideshare mission. This launch marks a significant advancement in WISeKey's vision to deliver quantum-secure, high-speed broadband connectivity through a growing constellation o…
RBC Capital Markets says European retail is splitting into two clear segments - low-price fast fashion under pressure from Shein, and higher-end consumers buying fewer, higher-quality items. Against headwinds including Middle East conflict disruption, EU customs adjustments and rising freight costs, the bank highlights four stocks it expects to out…
Lavazza reported a 15.7% increase in full-year revenue to 3.9 billion euros and an 8.8% rise in core profit to 340 million euros, with particularly strong growth in North America despite import tariffs. The company said the sector remains challenged by elevated green coffee costs, regulatory uncertainty and a logistics crisis that has increased exp…
Coeur Mining (CDE) has retraced sharply despite stronger cash flow, a manageable balance sheet and a meaningful production boost from the New Gold acquisition. A tactical long at $17.50 with a $15.90 stop targets $22.00 over the next ~45 trading days, playing for a recovery to the 50-day technical band and re-rating driven by buybacks, dividend ini…
Aptiv trades at an attractive enterprise-value-to-sales and EV/EBITDA multiple while sitting squarely in markets (ADAS, VCUs, vehicle electrification, software-defined vehicles) growing at double-digit rates. Technicals show oversold momentum and short interest is manageable. This trade plan buys the current weakness with a clear stop and a 180-tra…
InflaRx N.V. reported Phase 3 clinical data for vilobelimab in pyoderma gangrenosum (PG) featured at the 2026 American Academy of Dermatology Annual Meeting. The study was terminated early for futility but showed promising trends in clinical remission and ulcer healing compared to placebo, alongside a favorable safety profile. InflaRx plans to enga…
PROCEPT BioRobotics (PRCT) is a commercial-stage surgical robotics company focused on Aquablation for BPH. The stock trades at $26.49 with a $1.49B market cap after a February guidance cut and a subsequent wave of negative headlines. Fundamentals show rapid prior top-line growth, a strong liquidity position, and an EV/sales ratio that can compress …
Futures tied to the main U.S. benchmarks moved higher in early trading as oil prices climbed and investors continued to weigh ongoing conflict in the Middle East, now in its second month. Energy producers, refiners, and aluminum miners posted gains, while Sysco shares dropped after reports that the company is planning a roughly $29 billion acquisit…
A Swiss National Bank survey shows mobile payment app use plateaued last year while cash continues to be a widely supported payment method. Debit cards remain the dominant form for in-person purchases, and most respondents prefer retaining cash for reasons including anonymity and perceived control over spending.
Shares of Roma Green Finance climbed 35% after the company said its board approved a program to repurchase up to $100 million of Class A Ordinary Shares. The authorization, effective through December 31, 2028, allows repurchases through multiple methods and does not obligate the company to purchase any specific number of shares. Roma Green Finance …
Samsara just proved it can grow into profitability while moving deeper into large-enterprise accounts. With $1.89B ARR, accelerating $100K+ customer mix, and two consecutive GAAP profitable quarters, the company is trading at an attractive risk/reward for a long trade. Entry $30.00, target $42.00, stop $26.00 — long term (180 trading days).
Can-Fite BioPharma announced that its veterinary partner Vetbiolix has completed enrollment in a Phase 2 clinical trial testing Piclidenoson for osteoarthritis in dogs. Data is expected in Q3 2026. Vetbiolix has exercised its option to fully license Piclidenoson for veterinary use, with Can-Fite eligible for up to $325 million in payments subject t…
United Therapeutics shares climbed 12% Monday after the company reported that its pivotal TETON-1 study of nebulized Tyvaso achieved the trial's primary endpoint in patients with idiopathic pulmonary fibrosis (IPF). The therapy produced a statistically significant improvement in absolute forced vital capacity (FVC) versus placebo and reduced the ri…
U.S. dividend income funds have seen heavy inflows so far this year, drawing $24.1 billion in net new money and marking the strongest first quarter in four years, according to LSEG Lipper data. Investors and wealth managers cite geopolitical tensions, elevated oil prices linked to the Iran conflict, and a turbulent bond market as reasons for reallo…
